ATE459355T1 - Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung - Google Patents

Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung

Info

Publication number
ATE459355T1
ATE459355T1 AT03781632T AT03781632T ATE459355T1 AT E459355 T1 ATE459355 T1 AT E459355T1 AT 03781632 T AT03781632 T AT 03781632T AT 03781632 T AT03781632 T AT 03781632T AT E459355 T1 ATE459355 T1 AT E459355T1
Authority
AT
Austria
Prior art keywords
compounds
deficiencing
thiole
thiol
treating diseases
Prior art date
Application number
AT03781632T
Other languages
English (en)
Inventor
Brian Day
Leonard Velsor
Original Assignee
Nat Jewish Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Health filed Critical Nat Jewish Health
Application granted granted Critical
Publication of ATE459355T1 publication Critical patent/ATE459355T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03781632T 2002-10-31 2003-10-30 Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung ATE459355T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42280202P 2002-10-31 2002-10-31
US10/400,980 US20040087527A1 (en) 2002-10-31 2003-03-27 Methods for treatment of thiol-containing compound deficient conditions
PCT/US2003/034723 WO2004042020A2 (en) 2002-10-31 2003-10-30 Methods for treatment of thiol-containing compound deficient conditions

Publications (1)

Publication Number Publication Date
ATE459355T1 true ATE459355T1 (de) 2010-03-15

Family

ID=32179655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03781632T ATE459355T1 (de) 2002-10-31 2003-10-30 Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung

Country Status (6)

Country Link
US (3) US20040087527A1 (de)
EP (1) EP1562563B1 (de)
AT (1) ATE459355T1 (de)
AU (1) AU2003287398A1 (de)
DE (1) DE60331574D1 (de)
WO (1) WO2004042020A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
WO2004104022A2 (en) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
WO2005044984A2 (en) * 2003-10-15 2005-05-19 Trustees Of Dartmouth College Modulators of the abc transporter family and methods for their use
US20070275894A1 (en) * 2006-05-24 2007-11-29 Bruce Stanton Modulators of the ABC Transporter Family and Methods for Their Use
WO2007024741A2 (en) * 2005-08-24 2007-03-01 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
EP2167653A2 (de) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Behandlungsverfahren mit glutaredoxinen und ähnlichen agentien
CN101322700B (zh) * 2007-06-13 2010-08-25 中国科学院生物物理研究所 柚皮素和柚皮苷作为转化生长因子－β1信号通路抑制剂在制备药物中的应用
US20130345312A1 (en) * 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
CN109406467B (zh) * 2018-10-16 2021-01-29 商丘师范学院 用于atp检测的分裂适配体传感器及其应用
WO2020124152A1 (en) * 2018-12-19 2020-06-25 Monash University Assay for screening drugs
CN113476437A (zh) * 2021-08-10 2021-10-08 江南大学 刺芒柄花素在制备用于防治急性胰腺炎类疾病的药物中的应用
CN113797195B (zh) * 2021-08-20 2022-09-13 山东第一医科大学(山东省医学科学院) 3-芳基香豆素类化合物的应用、抗癌增敏组合物及抗癌组合物
CN117281808B (zh) * 2023-08-16 2026-06-26 双鸭山市人民医院 一种提高肝脏肿瘤治疗效果的药物组合物及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594814A (en) * 1897-11-30 Island
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5075116A (en) 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
US5010069A (en) * 1989-05-15 1991-04-23 Marion Laboratories, Inc. Stable liquid form of 5-aminosalicylic acid
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
US5766880A (en) 1992-10-27 1998-06-16 Queen's University At Kingston Isolated nucleic acid molecules encoding multidrug resistance proteins
US6025473A (en) 1992-10-27 2000-02-15 Queen's University At Kingston Multidrug resistance proteins
US5489519A (en) 1992-10-27 1996-02-06 Queen's University At Kingston Multidrug resistance protein
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
AU7482396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
RU2089179C1 (ru) 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US5994402A (en) * 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
AU3643497A (en) 1996-06-28 1998-01-21 National Jewish Center For Immunology And Respiratory Medicine Use of thioredoxin-like molecules for induction of mnsod to treat oxidative damage
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
FR2763845B1 (fr) 1997-05-30 2003-04-18 Centre Nat Rech Scient Produits anti-cancereux pour le traitement de la mucoviscidose
US6372772B1 (en) 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US6407065B1 (en) * 1998-01-23 2002-06-18 Novartis Ag VLA-4 antagonists
US6448472B1 (en) 1999-02-05 2002-09-10 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ectophosphatases for the conference of hormone and herbicide resistance
EP1242352A2 (de) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone und ihre analoge als hemmende wirkstoffe für angiogenese und verwandte krankheiten
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
WO2003086267A2 (en) * 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
EP1539941A4 (de) * 2002-08-27 2006-11-29 Adzyme und deren verwendungen
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
DE102005044156A1 (de) 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate

Also Published As

Publication number Publication date
WO2004042020A2 (en) 2004-05-21
EP1562563A4 (de) 2005-12-28
US20060058245A1 (en) 2006-03-16
AU2003287398A1 (en) 2004-06-07
AU2003287398A8 (en) 2004-06-07
DE60331574D1 (de) 2010-04-15
EP1562563A2 (de) 2005-08-17
US20040087527A1 (en) 2004-05-06
US20140162986A1 (en) 2014-06-12
EP1562563B1 (de) 2010-03-03
US7498047B2 (en) 2009-03-03
WO2004042020A3 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
DE60331574D1 (de) Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung
WO2007073518A3 (en) Compounds and methods for thiol-containing compound efflux and cancer treatment
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
DK0661987T3 (da) Morphogeninduceret leverregeneration
ATE281840T1 (de) Behandlung von diarrhoe
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
WO2007024741A3 (en) Methods for treatment of thiol-containing compound deficient conditions
DE60024969D1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
DE60230641D1 (de) Lentivirale vektoren zur behandlung von schmerzen
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties